[SCHEDULE 13G/A] Stoke Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Schedule 13G/A filing by FMR LLC (and Abigail P. Johnson) reports beneficial ownership in Stoke Therapeutics, Inc. (CUSIP 86150R107). The filing states 7,412,982 shares beneficially owned, representing 13.6% of the class as of the 06/30/2025 event date. Signatures dated 08/05/2025 certify the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.

• Issuer: STOKE THERAPEUTICS INC; principal office 45 WIGGINS AVENUE, BEDFORD, MA 01730.
• Reporting persons: FMR LLC (entity) and Abigail P. Johnson (individual).
• Voting/dispositive power: FMR reports 7,405,833 sole voting power and 7,412,982 sole dispositive power; no shared power reported.

Positive

• Material disclosure: FMR LLC and Abigail P. Johnson publicly report 7,412,982 shares (13.6%) beneficial ownership of STOK
• Clear power reporting: Filing specifies sole voting power of 7,405,833 and sole dispositive power of 7,412,982, with no shared power

Negative

• None.

Insights

Financial Analyst

TL;DR: FMR LLC reports a material passive stake—7.41M shares (13.6%)—in STOK, filed as a Schedule 13G/A.

The filing documents a sizable institutional position that meets the >5% disclosure threshold and is reported on Schedule 13G/A, indicating a passive intent. Key metrics are explicit: 7,412,982 shares beneficially owned and 13.6% of the class, with sole voting and dispositive power noted for FMR. The filing states holdings were acquired and are held in the ordinary course of business and not for control. For investors, this is material ownership information but routine in nature because no change-of-control intent or transaction is reported.

Corporate Governance Expert

TL;DR: This Schedule 13G/A is a routine passive-disclosure; it informs governance stakeholders but does not signal active control.

The disclosure identifies both an institutional beneficial owner (FMR LLC) and the named individual (Abigail P. Johnson) with aggregate ownership of 7,412,982 shares (13.6%). The filing includes certifications that the stake is held in the ordinary course and not for influencing control, consistent with Schedule 13G treatment. No shared voting or dispositive arrangements are reported, and no group formation or director nominations are indicated. Impact on governance is informational rather than directional absent further filings.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

STOKE THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

86150R107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 86150R107

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,405,833.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,412,982.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,412,982.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.6 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 86150R107

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,412,982.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,412,982.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: STOKE THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 45 WIGGINS AVENUE,BEDFORD,MA,USA,01730
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 86150R107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 7412982.00
(b)	Percent of class: 13.6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 7412982.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of STOKE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of STOKE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	08/05/2025

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson*
Date:	08/05/2025

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

How many STOK shares does FMR LLC report owning?

FMR LLC reports beneficial ownership of 7,412,982 shares of Stoke Therapeutics common stock.

What percentage of STOK outstanding does this filing represent?

The filing reports ownership equal to 13.6% of the class.

What type of SEC filing was submitted for STOK?

A Schedule 13G/A was filed, indicating a passive investor disclosure under the Securities Exchange Act.

What is the event date and filing signature date?

The event date requiring the filing is 06/30/2025; signatures on the filing are dated 08/05/2025.

Does the filing indicate FMR LLC intends to influence control of STOK?

No. The certification states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.